Simcere’s SIM0237 Receives NMPA Approval for Bladder Cancer Trial
China-based pharmaceutical innovator Simcere Pharmaceutical Group (HKG: 2096) has announced the receipt of an additional...
Abbisko Therapeutics to Unveil Phase I Data for ABSK011 and ABSK043 at ESMO 2023
Shanghai-based biotech powerhouse Abbisko Therapeutics Co., Ltd (HKG: 2256) is preparing to present the results...
MicroPort CardioFlow Medtech’s Third-Generation TAVI Product Achieves Initial Clinical Success
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG:...
Suzhou Inhal Pharma Secures Series A Funding for Expansion and Clinical Advances
Suzhou Inhal Pharma Co., Ltd, a China-based company dedicated to the research and development of...
CANbridge’s Maralixibat Receives Priority Review for PFIC Treatment in China
China-based rare disease specialist CANbridge Pharmaceuticals Inc. (HKG: 1228) has announced that a New Drug...
WuXi Biologics Launches WuXiUI: A Revolutionary Biotech Patent Platform
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced the...
Fosun Pharma Initiates Phase III Trial for ET-26 Anesthetic in China
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a leading healthcare conglomerate in China, has...
Kelun-Biotech to Present SKB264 Study Results for Metastatic Breast Cancer at ESMO
China-based pharmaceutical innovator Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) and its subsidiary Sichuan Kelun-Biotech...
China’s 9th National VBP Round Sets Rules for 42 Drugs Tender
The national drug alliance procurement office has issued a notification detailing the tendering rules for...
Vcanbio Receives NMPA Approval for Stem Cell Therapy VUM02 Clinical Trial
China-based biotechnology firm Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that...
Nona Biosciences Partners with Ingenia for Immunological Therapeutics Development
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142) and a biotech company...
SciClone Pharmaceuticals Gains FDA Nod for Thymalfasin COVID-19 Vaccine Booster Study
SciClone Pharmaceuticals Inc. (HKG: 6600), formerly a US-based and Nasdaq-listed company, has announced that it...
Atom Bioscience Secures $82M Series D to Advance Gout Treatment ABP-671
China-based Atom Bioscience, known formally as Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd, has reportedly...
Shanghai Pharma Health Commerce Secures $68M in Series C Funding Round
Shanghai Pharma Health Commerce Co., Ltd, a distinguished former subsidiary of China’s pharmaceutical giant Shanghai...
Hainan Poly Pharm’s PL002 Accepted for FDA Review for Liver Cancer Surgery
China-based pharmaceutical company Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that the Investigational...
NMPA Announces Pathway for Developing Generic Drugs Without Reference Preparation
The National Medical Products Administration (NMPA) has issued an announcement regarding the development of generic...
Novo Nordisk Reports 33% YOY Sales Increase, Boosts GLP-1 Drug Sales Forecast
Denmark-headquartered pharmaceutical giant Novo Nordisk (NYSE: NVO) provided a financial update last week, revealing a...
Pfizer’s Velsipity Approved by FDA for Ulcerative Colitis Treatment
China-based pharmaceutical company Everest Medicines (HKG: 1952) announced that its licensing partner, Pfizer Inc. (NYSE:...
China’s New Drug Quality Management Measures to Take Effect in 2024
The State Administration for Market Regulation (SAMR) has released the “Drug Operation and Use Quality...